FDA Grants Senza5 CART5 Regenerative Designation
Vittoria Biotherapeutics' CD5-edited CAR-T therapy receives RMAT and Orphan Drug Designations for relapsed or refractory peripheral T-cell lymphoma.
Updated on Nov. 10, 2026 in Biotech

The FDA granted Regenerative Medicine Advanced Therapy designation and Orphan Drug Designation to Senza5 CART5, an investigational CD5-edited autologous CAR-T cell therapy developed by Vittoria Biotherapeutics. The therapy is being developed for relapsed or refractory CD5-positive peripheral T-cell lymphoma.
Why it matters
The RMAT designation provides early and frequent FDA engagement to support planned pivotal development of the therapy, while Orphan Drug Designation is intended to encourage treatments for rare diseases. Together they signal regulatory support for a treatment aimed at a population with limited options.
The therapy uses a dual-population CAR-T product: CD5-edited, CD5-directed cells for antitumor activity alongside CD5-negative, CAR-negative T cells for immune reconstitution, produced in a five-day process. Phase 1 efficacy and safety results have not yet been released.
The players
Vittoria Biotherapeutics
A clinical-stage immunotherapy company developing engineered T-cell therapies, headquartered in Philadelphia.
University of Pennsylvania
A private Ivy League research university whose institution licenses the Senza5 technology exclusively to Vittoria Biotherapeutics.
U.S. Food and Drug Administration
The federal agency responsible for regulating drugs and biologics in the United States, which granted the designations.
The details
VIPER-101 produces CD5-edited, CD5-directed CAR-T cells alongside companion CD5-negative, CAR-negative T cells, built on the Senza5 platform licensed exclusively from the University of Pennsylvania. Results from the Phase 1 trial, registered as NCT06420089, will be presented in an oral session at the 68th ASH Annual Meeting.
Timeline
July 2026: Orphan Drug Designation granted to Senza5 CART5.
November 10, 2026: FDA RMAT and Orphan Drug Designations announced.
December 14, 2026: VIPER-101 Phase 1 results presented at the ASH Annual Meeting.
Roadmap
The RMAT designation, created under the 21st Century Cures Act, is the FDA's expedited pathway for regenerative therapies addressing serious conditions. Senza5 CART5 extends that pathway into engineered CAR-T therapy for relapsed or refractory peripheral T-cell lymphoma, a cancer type with limited treatment options.
For patients with relapsed or refractory peripheral T-cell lymphoma, the designations signal a potential path to a new treatment option. Approval timing is not yet set, and the therapy remains investigational.
The takeaway
Regulatory designations like RMAT and Orphan Drug status do not guarantee approval, but they reflect FDA recognition of unmet need and earlier, closer regulatory engagement. Readers tracking cell therapy should watch for the Phase 1 results in December 2026.
What happens next
Results from the Phase 1 VIPER-101 trial will be presented at the 68th ASH Annual Meeting on December 14, 2026.
Further reading
Explore more Biotech coverage for context on engineered cell therapies and FDA regulatory pathways.
Source note: This article includes information reported by The Manila times.






